On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA approved compounded drugs. On the same day, the HHS General Counsel announced on social ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

The compounding pharmacy market, valued at approximately USD 15.1 billion in 2025, is forecast to reach nearly USD 20 billion by 2030, registering a compound annual growth rate (CAGR) of 5.7%, says ...

Legislative sessions are underway in most states, and some have introduced novel legislation to regulate compounded medications, including ...

Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "U.S. Compounding Pharmacy Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S.

An ordered pharmaceutical compounding process for use in 503A pharmacies, 503B outsourcing facilities, pharmaceutical industry, and other applications. Compounded pharmaceutical dosage forms may be ...

Unlike conventional pharmacies, which mostly dispense premade drugs in standard doses, compounding pharmacies make, or "compound," medications on the premises, according to federal guidelines. For ...

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling. Performing calculations for the formulation of pharmaceutical dosage forms and ...

A year ago, the FDA took the unusual step of inserting itself into the controversy over the KV Pharmaceutical drug known as Makena, which the agency had approved for premature births under the Orphan ...